10.23.2023 Update: In the context of limited supply during the 2023–2024 RSV season, CDC recommends prioritizing available nirsevimab 100mg doses (for children >=5kg) for infants at the highest risk for severe RSV disease:
- young infants (age <6 months)
- infants with underlying conditions that place them at highest risk for severe RSV disease
Recommendations for using 50mg (for children <5kg) doses remain unchanged at this time. CDC further recommends that providers suspend using nirsevimab in palivizumab-eligible children aged 8–19 months for the 2023–2024 RSV season. These children should receive palivizumab per American Academy of Pediatrics (AAP) recommendations.
Nirsevimab should continue to be offered to American Indian and Alaska Native children aged 8–19 months who are not palivizumab-eligible and who live in remote regions, where transporting children with severe RSV for escalation of medical care is more challenging or in communities with known high rates of RSV among older infants and toddlers.
As healthcare experts anticipate a winter respiratory surge, the FDA recently approved nirsevimab, a monoclonal antibody designed to target Respiratory Syncytial Virus (RSV). The American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), and Centers of Disease Control and Prevention (CDC) have all recommended the treatment which has exhibited its potential to reduce the severity of RSV infections.
Resources for Providers
Understanding nirsevimab, and effectively communicating its benefits and availability to parents is essential. Explore the resources below for information on RSV clinical care, surveillance, and prevention:
RSV Clinical Care
- Centers for Disease Control and Prevention: Respiratory Syncytial Virus Infection (RSV)
- Pediatric Preparedness for the Winter Viral Surge
- WRAP-EM Pediatric Surge Playbook
RSV Surveillance
- National Emergency Department Visits for COVID-19, Influenza, and Respiratory Syncytial Virus
- Respiratory Syncytial Virus (RSV) Surveillance
- RSV-NET Interactive Dashboard
Nirsevimab and RSV Prevention
- Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals
- AAP: Nirsevimab Frequently Asked Questions
- AAP Respiratory Syncytial Virus (RSV) Prevention
- CDC: Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices
Resources for Families
Understanding Respiratory Syncytial Virus (RSV) and its prevention is crucial for children’s well-being. Explore the resources below to learn more about RSV, its treatment options like nirsevimab, and strategies to protect little ones.